유전자재조합 응고인자 시장 : 제품 유형별, 혈우병 유형별, 최종사용자별, 지역별 규모, 점유율 및 성장 분석과 산업 예측(2026-2033년)

Recombinant Coagulation Factors Market size was valued at USD 14.97 Billion in 2024 and is poised to grow from USD 16 Billion in 2025 to USD 27.29 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The market for recombinant coagulation factors is experiencing significant growth due to rising incidences of hemophilia and other bleeding disorders, coupled with heightened consumer demand for both plasma-derived and recombinant therapies. Advances in recombinant DNA technology enable efficient production of critical proteins, such as Factor VIII, Factor IX, and von Willebrand factor, leading to effective therapeutic applications. Furthermore, ongoing research and development efforts, along with an increasing number of product approvals, are driving innovation in this sector. While challenges such as high treatment costs and competition from lower-cost plasma alternatives exist, the growing trend toward prophylactic treatments for hemophilia presents substantial opportunities for market expansion in this dynamic landscape, characterized by a decreasing risk of infectious agent transmission from these recombinant products.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Coagulation Factors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Coagulation Factors Market Segments Analysis

Global Recombinant Coagulation Factors Market is segmented by Product Type, Hemophilia Type, End User and region. Based on Product Type, the market is segmented into Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor. Based on Hemophilia Type, the market is segmented into Hemophilia A and Hemophilia B. Based on End User, the market is segmented into Hospitals, Clinics and Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Coagulation Factors Market

The Recombinant Coagulation Factors market is experiencing notable growth driven by a sustained rise in research and development investments and funding within the pharmaceutical and biotechnological sectors. Leading companies in this market are heavily focused on developing advanced technological products, which enhances the adoption of Recombinant Coagulation Factors in both developed and emerging economies worldwide. This trend in increased utilization is further fueled by a growing number of product approvals for innovative recombinant coagulation factors, significantly contributing to the overall expansion of the global market for these essential therapeutic agents.

Restraints in the Recombinant Coagulation Factors Market

The growth of the recombinant coagulation factors market is hindered by several key factors. Primarily, the high cost associated with hemophilia treatment presents a significant barrier, especially when more affordable plasma coagulation treatments are readily accessible in the market. Additionally, the availability of alternative therapies that serve as substitutes for recombinant coagulation factors further exacerbates this challenge. As patients and healthcare providers often seek cost-effective solutions, the competition posed by these alternatives may limit the market's expansion. Consequently, these factors contribute to a more complex landscape for recombinant coagulation factor adoption and utilization.

Market Trends of the Recombinant Coagulation Factors Market

The global recombinant coagulation factors market is experiencing significant growth driven by an increasing prevalence of blood disorders, particularly hemophilia, and the rising adoption of advanced recombinant technologies in treatment modalities. Patients and healthcare providers are gravitating towards recombinant coagulation factors due to their improved safety profile, lower risk of viral transmission, and enhanced therapeutic efficacy compared to traditional therapies. Additionally, ongoing innovation in product formulation and delivery mechanisms, alongside a growing awareness of treatment options and patient-centric healthcare initiatives, are further propelling market expansion. This trend reflects a robust shift in the approach towards managing blood coagulation disorders globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Coagulation Factors Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Recombinant Factor VIII
• Recombinant Factor IX
• Von Willebrand Factor

Global Recombinant Coagulation Factors Market Size by Hemophilia Type & CAGR (2026-2033)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Recombinant Coagulation Factors Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Organizations

Global Recombinant Coagulation Factors Market Size & CAGR (2026-2033)

• North America (Product Type, Hemophilia Type, End User)
  • US
  • Canada
• Europe (Product Type, Hemophilia Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hemophilia Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hemophilia Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hemophilia Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Swedish Orphan Biovitrum AB (Sobi) (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freeline Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations